ST SC Pharmaceuticals: Eptinezumab injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia
ST SC Pharmaceuticals recently obtained the marketing authorization for Eptifibatide Injection issued by the Therapeutic Goods Administration (TGA) of Australia. This drug is suitable for patients undergoing non-emergency percutaneous coronary intervention, as well as for the treatment of unstable angina or non-Q wave myocardial infarction. This authorization will help the company expand its overseas market and improve its performance
According to the Zhitong Finance APP, *ST Pharmaceuticals (002693.SZ) announced that the company recently received a marketing authorization for Eptifibatide Injection issued by the Therapeutic Goods Administration (TGA) of Australia. Approved indications: suitable for patients undergoing non-emergency percutaneous coronary intervention and coronary artery stent implantation; suitable for the treatment of unstable angina or non-Q-wave myocardial infarction patients.
The marketing authorization for Eptifibatide Injection issued by the Therapeutic Goods Administration of Australia indicates that the company's Eptifibatide Injection is qualified for sale in Australia. This will have a positive impact on the company's expansion into overseas markets and enhance the company's performance
